Abstract
Ovalbumin challenge models of asthma offer many opportunities for increasing our understanding of the pathogenetic mechanisms underlying this disease, as well as for identifying novel therapeutic targets. There is no single “classical” model, because numerous alternatives exist with respect to the choice of mouse strain, method of sensitisation, route and duration of challenge, and approach to assessing the host response. Moreover, the limitations of these models need to be recognised when attempting to interpret experimental findings. Nevertheless, careful use of well-defined models allows investigators to answer specific questions that are otherwise difficult to address.
Keywords: Asthma, animal models, airway inflammation, airway hyper-responsiveness, airway remodelling
Current Drug Targets
Title: The “Classical” Ovalbumin Challenge Model of Asthma in Mice
Volume: 9 Issue: 6
Author(s): Rakesh K. Kumar, Cristan Herbert and Paul S. Foster
Affiliation:
Keywords: Asthma, animal models, airway inflammation, airway hyper-responsiveness, airway remodelling
Abstract: Ovalbumin challenge models of asthma offer many opportunities for increasing our understanding of the pathogenetic mechanisms underlying this disease, as well as for identifying novel therapeutic targets. There is no single “classical” model, because numerous alternatives exist with respect to the choice of mouse strain, method of sensitisation, route and duration of challenge, and approach to assessing the host response. Moreover, the limitations of these models need to be recognised when attempting to interpret experimental findings. Nevertheless, careful use of well-defined models allows investigators to answer specific questions that are otherwise difficult to address.
Export Options
About this article
Cite this article as:
Kumar K. Rakesh, Herbert Cristan and Foster S. Paul, The “Classical” Ovalbumin Challenge Model of Asthma in Mice, Current Drug Targets 2008; 9 (6) . https://dx.doi.org/10.2174/138945008784533561
DOI https://dx.doi.org/10.2174/138945008784533561 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Use of Microarrays to Characterize Neuropsychiatric Disorders: Postmortem Studies of Substance Abuse and Schizophrenia
Current Molecular Medicine The Host Complement System and Arbovirus Pathogenesis
Current Drug Targets Infrared-Spectroscopy: A Non-Invasive Tool for Medical Diagnostics and Drug Analysis
Current Medicinal Chemistry Pharmacological Treatment in Chronic Obstructive Pulmonary Disease
Current Respiratory Medicine Reviews Role of Iron Deficiency and Overload in the Pathogenesis of Diabetes and Diabetic Complications
Current Medicinal Chemistry Anti-Inflammatory Activities of α2-Agonists
Current Drug Targets - Inflammation & Allergy Targeted Drugs and Nanomedicine: Present and Future
Current Pharmaceutical Design Role of Plasmacytoid Dendritic Cells in Lung-Associated Inflammation
Recent Patents on Inflammation & Allergy Drug Discovery The Protein Profile of Fibroblasts: The Role of Proteomics
Current Proteomics Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology
Current Drug Targets Platelet-Activating Factor (PAF): A Review of its Role in Asthma and Clinical Efficacy of PAF Antagonists in the Disease Therapy
Recent Patents on Inflammation & Allergy Drug Discovery Matrix Metalloproteinase-9 and Airway Remodeling in Asthma
Current Drug Targets - Inflammation & Allergy Pulmonary Hypertension: Current Therapy and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry Pharmacogenomics in Drug Induced Liver Injury
Current Drug Metabolism Chronopharmaceutical Delivery of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial [Hot Topic: Essential Fatty Acids (Guest Editor: Undurti N. Das)]
Current Pharmaceutical Biotechnology Cardiovascular Effects of Omega-3 Free Fatty Acids.
Current Vascular Pharmacology Efficacy of Andolast in Mild to Moderate Asthma: A Randomized, Controlled, Double-Blind Multicenter Study (The Andast Trial)
Current Pharmaceutical Design Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Respiratory Tolerance in the Protection Against Asthma
Current Drug Targets - Inflammation & Allergy